Adalimumab, a tumor necrosis factor inhibitor (TNFi), received approval from the U.S. Food and Drug Administration for use in rheumatoid arthritis (RA) in 2002, ankylosing spondylitis in 2006, and juvenile idiopathic arthritis (JIA) in 2008. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.